Apricus Biosciences said in a release that its CEO, Richard Pascoe, recently addressed the 2017 BIO Investor Forum in San Francisco, where he updated attendees on the company’s Vitaros, an erectile dysfunction treatment under development in the U.S.
Apricus, a biopharmaceutical company, focuses on medicines in urology and rheumatology. The company said in the release it currently has two product candidates in development, Vitaros and RayVa.
Vitaros is being developed for the treatment of erectile dysfunction and is in-license from Warner Chilcott, a subsidiary of Allergan, the release said.
The release said RayVa is currently in phase 2 development for the treatment of Raynaud’s syndrome. The product is secondary to scleroderma.
The San Francisco conference, held by Biotechnology Innovation Organization (BIO), is one of the largest international biotechnology industry investor gatherings. BIO is of the world’s largest trade associations, represents biotechnology companies, academic institutions, state biotechnology centers and other organizations across the U.S. and in 30 other countries.
